Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
|
25822088 |
2015 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
|
25822088 |
2015 |
Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
Most HCC are associated with chronic infection by Hepatitis B Virus while a G → T mutation at codon 249 of the TP53 gene, R249S, specific for exposure to aflatoxin, is detected in tumors for up to 30% of cases.
|
22675488 |
2012 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
Most HCC are associated with chronic infection by Hepatitis B Virus while a G → T mutation at codon 249 of the TP53 gene, R249S, specific for exposure to aflatoxin, is detected in tumors for up to 30% of cases.
|
22675488 |
2012 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot p53 mutant, R246S -- the mouse equivalent of human R249S, which is associated with hepatocellular carcinomas.
|
18477611 |
2008 |
Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
We have therefore generated 'knock-in' mouse embryonic stem (ES) cells to investigate the effects of expressing a commonly found hot-spot p53 mutant, R246S -- the mouse equivalent of human R249S, which is associated with hepatocellular carcinomas.
|
18477611 |
2008 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
These results suggest the level of p53 expression could determine if the HCC cells would go into cell cycle arrest or apoptosis.
|
17191126 |
2007 |
Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
These results suggest the level of p53 expression could determine if the HCC cells would go into cell cycle arrest or apoptosis.
|
17191126 |
2007 |
Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.
|
9029167 |
1997 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
Molecular biological analyses of the induced lesions revealed point mutations in the p53 gene in 60.9% of HCCs, and elevated expression of mRNAs for p53, c-myc, c-fos, TGF-alpha, TGF-beta1, alpha-fetoprotein, GST-P, and GGT, and decreased mRNA expression of EGF and EGFR in HCCs when compared to controls.
|
9029167 |
1997 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen.
|
8033108 |
1994 |
Liver carcinoma
|
1.000 |
Therapeutic
|
disease |
CTD_human |
Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen.
|
8033108 |
1994 |
Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|